LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

Rhea-AI Summary

LIR Life Sciences (OTC:BBCMF) reported positive interim preclinical results from a comparative mouse study of a CPP-enabled, needle-free topical semaglutide formulation. Treated animals showed reduced blood glucose after an oral glucose challenge versus untreated controls, with a flattened glucose curve approaching the injectable comparator.

Findings suggest the CPP transdermal platform may deliver pharmacologically meaningful levels of GLP/GIP-based peptides across skin and support further dose refinement and continuation of comparative studies.

Positive

• Topical CPP semaglutide reduced blood glucose versus untreated controls
• CPP topical profile approached injectable semaglutide in glucose control
• Flattened glucose curve observed indicating sustained glucose control
• Preclinical data support continued funding of additional comparative study
• Provides in vivo proof-of-concept for CPP-enabled transdermal peptide delivery

Negative

• Interim results are preclinical in mice, not human clinical data
• No quantitative efficacy, dose, or safety figures disclosed in the release
• Translatability from mouse model to human clinical efficacy remains unproven

VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compared with untreated controls, indicating pharmacologically meaningful activity in this model.

The study compares a topical, skin-applied CPP formulation of semaglutide, a GLP-1 analogue representative of GLP/GIP-based therapies, against injectable semaglutide and untreated controls in a glucose tolerance model. These interim data represent one of the first demonstrations, in a controlled in vivo setting, that a CPP-enabled topical formulation of a GLP/GIP-based therapy can approach the glucose control profile of an injectable comparator. Observing a flattened glucose curve from a skin-applied formulation is a key technical milestone for the Company's platform. It supports the underlying scientific thesis that CPP-based systems may be able to move large peptide drugs across the skin barrier at levels that are not only measurable, but functionally meaningful in a standard metabolic model.

In this interim analysis, animals that received the CPP-formulated topical semaglutide showed a reduction in blood glucose compared with untreated controls following a standardized oral glucose challenge. While control animals exhibited a pronounced spike in blood sugar after glucose administration, both the injected semaglutide group and the CPP-enabled topical group demonstrated effective blunting of this spike and a faster return toward baseline. Importantly, blood glucose levels in the CPP topical group remained stable over the observation period. These findings indicate that the CPP-enabled topical formulation is likely delivering active drug across the skin barrier at pharmacologically meaningful levels and is achieving sustained glucose control in this model.

These interim results provide preliminary in vivo support for LIR's CPP-enabled transdermal platform for GLP/GIP-based therapies. Further, this demonstration with topical CPP semaglutide is an important step toward refining formulations, confirming dose ranges and guiding the path to future studies. These findings also support the continued funding of an existing comparative study utilizing a different GLP/GIP-based therapy, for which results are anticipated shortly.

"Even at this interim stage, we are encouraged by what the study is showing. Our CPP-enabled topical formulation is producing a meaningful glucose-lowering effect in a standard model. This is an important step because it supports the thesis of pursuing a needle-free approach and gives us a clear basis for the next phase of work, including refining the formulation, narrowing the dose range, and completing the additional comparative studies already underway," said Edward Mills, CEO of LIR Life Sciences.

About LIR Life Sciences Corp.
LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

ON BEHALF OF LIR LIFE SCIENCES CORP.,

"Dr. Edward Mills,"
Chief Executive Officer

For more information, please contact:

Dr. Edward Mills
Chief Executive Officer
Tel: +1 888 436 7772
Email: investors@lirlife.com

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note Regarding Forward-Looking Information
This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the filing of the provisional patent application, the research and development activities of the Company, the financial and business prospects of the Company, its assets and other matters. In particular, forward-looking information includes statements regarding the Company's transdermal delivery platform, the potential compatibility of the platform with GLP/GIP-based medicines, the anticipated outcomes of preclinical studies, and the potential development of future needle-free metabolic therapies. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

SOURCE: Lir Life Sciences Corp.

View the original press release on ACCESS Newswire

FAQ

What did LIR Life Sciences (BBCMF) announce on January 29, 2026 about topical semaglutide?

They reported interim mouse-study results showing a CPP topical semaglutide lowered blood glucose versus untreated controls. According to the company, the topical formulation produced a flattened glucose curve that approached the injectable comparator in a standardized glucose tolerance model.

How effective was the CPP-enabled topical semaglutide compared with injectable semaglutide in the BBCMF study?

The topical formulation approached the glucose-control profile of the injectable comparator in mice. According to the company, both injected and CPP topical groups blunted the glucose spike and returned toward baseline faster than controls.

Does LIR (BBCMF) report human clinical results for its CPP transdermal platform?

No, the announcement describes interim preclinical mouse-study results only, not human trials. According to the company, these are early in vivo data intended to guide formulation and dosing ahead of future studies.

What are the next steps LIR (BBCMF) plans after these interim preclinical results?

LIR intends to refine formulations, confirm dose ranges, and complete additional comparative studies already underway. According to the company, the data support continued funding and guide the path to future studies.

Do the BBCMF results include safety or dose information for the topical CPP semaglutide?

No specific safety, dose, or quantitative efficacy figures were provided in the interim release. According to the company, the findings are preliminary and aimed at informing formulation and dosing in follow-up studies.